LACTOLOGY FOUNDATION

Intestinal adsorbents (ATC A07B) are locally acting antidiarrheal agents that bind toxins and other substances in the gut lumen, with minimal systemic absorption and generally low transfer into breast milk.perplexity

ATC A07B overview

The ATC group A07B “Intestinal adsorbents” includes activated charcoal preparations (A07BA), bismuth preparations (A07BB), and other intestinal adsorbents such as diosmectite (A07BC). These agents are used as symptomatic treatment in acute diarrhea, flatulence, and conditions with increased gastric acidity, acting mainly within the gastrointestinal tract.perplexity

Mechanism of action

Intestinal adsorbents exert their effect by physical adsorption of bacterial toxins, xenobiotics, gases, and other molecules on their large surface area, thereby reducing their bioavailability and irritant effect on the intestinal mucosa. Additional antacid activity contributes to a reduction in gastric acidity, which may further alleviate gastrointestinal symptoms.perplexity

Main therapeutic indications

Drugs in class A07B are primarily indicated for acute diarrhea of various etiologies (non‑invasive infectious diarrhea, dietary indiscretions, toxin‑mediated diarrhea), often as adjuncts to rehydration. They are also used in flatulence, dyspeptic complaints with gas formation, and hyperacidity, and activated charcoal is used at higher doses for gastrointestinal decontamination in acute poisoning.perplexity

Use in lactation – general considerations

Because A07B drugs act locally in the gut and are negligibly absorbed systemically, transfer into human milk is expected to be minimal to none, especially for activated charcoal and non‑absorbed mineral adsorbents. Their use during breastfeeding is generally considered compatible, provided that maternal dosing remains within therapeutic ranges and that the underlying cause of diarrhea in the mother does not itself pose a risk for the breastfed infant (for example, severe infectious diarrhea requiring isolation or systemic therapy).perplexity

Pharmacokinetics relevant to breastfeeding

Activated charcoal is not absorbed from the gastrointestinal tract; it remains within the lumen and is eliminated in the feces, which practically precludes passage into breast milk. Other non‑absorbed adsorbents such as diosmectite and similar clays also have negligible systemic bioavailability, while some bismuth compounds may undergo limited absorption; however, systemic exposure at antidiarrheal doses remains low.perplexity

Maternal safety and adverse effects

Common adverse effects of intestinal adsorbents include nausea, constipation, headache, and hypersensitivity reactions; in the context of diarrhea, constipation is often dose‑limiting. They are contraindicated in patients with intestinal obstruction or severe motility disorders, and caution is advised in individuals with known hypersensitivity to the active substance or excipients.perplexity

Potential effects on the breastfed infant

Given the minimal transfer into milk, direct drug exposure in the breastfed infant is expected to be extremely low and clinically insignificant for activated charcoal and non‑absorbed adsorbents. Indirect effects may occur if maternal adverse events (for example severe constipation or vomiting) impair her ability to breastfeed or if the maternal underlying disease requires temporary interruption of breastfeeding.perplexity

Bismuth‑containing preparations

Bismuth preparations (A07BB) combine adsorbent, mild antimicrobial, and mucosal protective actions and are used in some regions as antidiarrheal agents. Limited systemic absorption and short‑term use at therapeutic doses suggest low risk in lactation, but due to the presence of heavy metal ions, it is prudent to avoid prolonged or high‑dose courses during breastfeeding and to prefer better‑characterized non‑absorbed alternatives when possible.perplexity

Contraindications in pregnancy and lactation labels

Some local product labels formally contraindicate intestinal adsorbents in pregnancy and lactation or recommend caution, largely on the basis of limited controlled data rather than documented harm. Clinically, their use can be justified during breastfeeding when clearly indicated, after assessment of the maternal condition, alternative treatments, and the self‑limited nature of many diarrheal illnesses.perplexity

Practical recommendations for breastfeeding women

For mild, self‑limited diarrhea in breastfeeding women, oral rehydration and dietary measures are first‑line; if an adsorbent is needed, non‑absorbed agents such as activated charcoal or diosmectite can be preferred. Products combined with additional active ingredients (for example, propolis, herbal extracts, salicylates) should be evaluated individually for lactation safety, and prolonged courses of bismuth‑containing agents should be avoided in favor of shorter, symptom‑guided use.perplexity

Infant monitoring

Routine breastfeeding can usually continue while the mother receives an A07B intestinal adsorbent, without the need for dose‑timing relative to feeds, given the negligible milk transfer. Nevertheless, the infant should be monitored for general well‑being, stool pattern changes, and signs of gastrointestinal infection that might reflect transmission of the underlying maternal illness rather than drug exposure.perplexity

Risk–benefit assessment

In breastfeeding, the benefit of symptom control (allowing adequate hydration, nutrition, and continuation of lactation) generally outweighs the theoretical risks of intestinal adsorbents when used appropriately and short‑term. Clinical judgment should consider etiology of diarrhea, severity of maternal symptoms, comorbidities, and availability of alternative therapies, with documentation of the risk–benefit discussion in the medical record.perplexity